Findings to be presented at the 2019 American Society of Clinical Oncology’s Genitourinary Cancers Symposium
San Francisco and Culver City, CA – February 14, 2019 – Scientific teams from NantHealth (NASDAQ: NH) and NantOmics will present two posters at the American Society of Clinical Oncology’s (ASCO) Genitourinary Cancers Symposium this week. The two companies, respective leaders in molecular profiling research and genomic testing solutions, teamed together to explore the significance of RNA expression and individual biomarkers in determining why some patients do not respond to targeted cancer therapies based on DNA genomic profiling alone.
The first poster session will provide insights on individual biomarkers obtained from liquid biopsies that may potentially improve immune checkpoint therapies for prostate cancer. The second session will feature research, conducted with experts from the UC San Diego Health Moores Cancer Center, that demonstrates the benefits of examining discrepancies between DNA alterations and RNA expression that could be the cause of treatment failure for people with metastatic kidney, bladder, and prostate cancer.
“While next generation sequencing for advanced cancers has become routine, not all patients are responding to targeted treatments based solely on DNA genomic profiling,” said Sandeep “Bobby” Reddy, MD, Chief Medical Officer, NantHealth. “It is becoming clear that we must delve deeper into RNA expression, as well as identify key biomarkers, to develop effective cancer treatments and therapies.”
NantHealth and NantOmics will present the following posters at this year’s Genitourinary Cancers Symposium:
- Concomitant characterization of androgen receptor (AC) and immune checkpoints (ICs) in cell-free (cf) DNA and RNA from patients with metastatic castration resistant prostate cancer (mCRPC) – 11:30AM-1:00PM & 5:30PM-6:30PM, 2/14/2019, Session A, Board M21, Abstract #286
- RNA sequencing in addition to next generation sequencing in advanced genitourinary cancers reveals transcriptomic silencing of DNA mutations: Implications for resistance to targeted therapeutics – 7:00AM-7:55AM & 12:30PM-2:00PM, 2/16/2019, Session C, Board E22, Abstract #583
The 2019 Genitourinary (GU) Cancers Symposium is a three-day scientific and educational meeting in San Francisco designed to meet the needs of physicians and other members of the cancer care and research community who diagnose, treat, and study GU malignancies.
About NantHealth
NantHealth, a member of the NantWorks ecosystem of companies, provides leading solutions across the continuum of care for patients, physicians, payors and biopharmaceutical organizations to enable cutting edge data and technology focused on fulfilling the goal to empower clinical decision support and improved patient outcomes. NantHealth’s GPS Cancer® molecular profiling provides comprehensive DNA, RNA, tumor-normal analysis combined with pharmacogenomics data. Liquid GPS® provides a non-invasive testing of cfDNA and cfRNA to monitor and potentially select targeted therapy, chemotherapy, and immunotherapy. NantHealth’s Precision Insights® Portal is the only solution available to blend guidelines-based regimen information powered by the Eviti® evidence-based platform with personalized insights from GPS Cancer® and Liquid GPS® to provide oncologists an integrated view of treatment options informed by both standard of care and patient-specific molecular insights. For more information, please visit www.nanthealth.com.
About NantOmics:
NantOmics, a member of the NantWorks ecosystem of companies, invented and developed the technologies that drive NantHealth’s GPS Cancer® platform. GPS Cancer® provides actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care. NantOmics is the first molecular analysis company to pioneer an integrated approach to unearthing molecular variances and profiles that initiate and drive cancer, by analyzing both normal and tumor cells from the same patient and following identified variances from DNA to RNA to protein to drug. Having pioneered tumor-normal DNA sequencing and introduced whole RNA transcriptomic analysis to better inform clinical treatment decisions, NantOmics has provided molecular insights for thousands of cancer patients.
NantOmics has a highly scalable cloud-based infrastructure capable of storing and processing thousands of genomes a day, computing genomic variances in near real-time and correlating proteomic pathway analysis with quantitative gene expression and pharmacogenomic signatures, which guides the use of immunotherapies, chemotherapies and targeted therapies. Clinical studies for neoepitope vaccines using NantOmics’ proprietary technologies and novel artificial intelligence platforms are currently underway. For more information please visit www.nantomics.com.
Media Contact:
Jen Hodson
NANT
jhodson@nantworks.com